Labcorp has been selected as the winning bidder of select assets of Invitae for a sum of USD 239 million. The transaction is expected to be closed in the third quarter of 2024 after the regulatory approval, following a court hearing currently scheduled for May 6.
Through this transaction, Labcorp would acquire Invitae’s assets, which would be auctioned through a voluntary bankruptcy protection process. Post-acquisition, Labcorp intends to harness Invitae's assets to scale its specialty testing in areas like oncology and rare diseases. This acquisition is expected to generate annual revenue of approximately USD 275 million–300 million for Labcorp, most of which will come from specialty testing.
Labcorp, a subsidiary of Laboratory Corporation of America Holdings, is a life sciences healthcare company that provides services in diagnostics, drug development and manufacturing, research and analysis, drug safety testing, and clinical trials.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.